{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT05607095","nct_id":"NCT05607095","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05607095. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants have metastatic uveal melanoma who will undergo surgical excision to generate LN-144/LN-145","label":"Participants with Metastatic Uveal Melanoma","type":"EXPERIMENTAL"},{"description":"Participants have metastatic sarcoma who will undergo surgical excision to generate LN-144/LN-145","label":"Participants with Metastatic Sarcoma","type":"EXPERIMENTAL"},{"description":"Patients with angiosarcoma who will undergo surgical excision to generate LN-144/LN-145","label":"Expansion Patients with angiosarcoma","type":"EXPERIMENTAL"}],"collaborators":["Iovance Biotherapeutics, Inc."],"completion_date":{"date":"2027-05-01","type":"ESTIMATED"},"conditions":["Uveal Melanoma","Melanoma","Metastatic Uveal Melanoma","Metastatic Melanoma"],"enrollment":{"count":40,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Lifileucel (LN-144/LN-145)","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2026-09-15","lead_sponsor":"Memorial Sloan Kettering Cancer Center","official_title":"A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) for Patients With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-05-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Adverse events as evaluated by CTCAE v5.0","timeFrame":"Up to 3 years"}],"references":[],"start_date":{"date":"2022-11-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma","url":"https://clinicaltrials.gov/study/NCT05607095"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05607095"}